Sanofi and Regeneron Pharmaceuticals, Inc. announced their intent to simplify their antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) by...
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for Praluent (alirocumab)...
The FDA has approved Praluent (alirocumab), from Regeneron, to reduce the risk of heart attack, stroke, and unstable angina requiring...
The National Institute for Health and Care Excellence has issued draft guidance not recommending Praluent (alirocumab)from Sanofi,for people with high...
The European Commission (EC) has approved a new indication for Praluent (alirocumab), from Sanofi + Regeneron, to reduce cardiovascular (CV)...
Sanofi and Regeneron Pharmaceuticals have announced detailed positive results from ODYSSEY ESCAPE, a Phase III trial which evaluated Praluent (alirocumab)...
Regeneron Pharma has presented Phase III ODYSSEY HoFH trial results from a late-breaking presentation, demonstrating the effect of Praluent (alirocumab) in patients with homozygous familial hypercholesterolemia (HoFH).
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the ODYSSEY OUTCOMES trial met its primary endpoint, showing Praluent (alirocumab) significantly reduced...